These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1307353)

  • 1. Effect of bed time intermediate acting insulin in NIDDM subjects refractory to a combination of sulphonylureas and biguanides.
    Seshiah V; Shanker R; Madhavan R; Venkataraman S; Sundaram A; Seshasaianam C; Sankaran JR
    J Assoc Physicians India; 1992 Oct; 40(10):666-8. PubMed ID: 1307353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term observations with oral hypoglycemic drugs: sulphonylureas, biguanides and their combination.
    Patel JC; Dhirawani MK; Doshi JC
    Indian J Med Sci; 1970 Jul; 24(7):393-403. PubMed ID: 5523184
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure.
    Soneru IL; Agrawal L; Murphy JC; Lawrence AM; Abraira C
    Diabetes Care; 1993 Jun; 16(6):896-901. PubMed ID: 8325203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?
    Trischitta V; Italia S; Raimondo M; Guardabasso V; Licciardello C; Runello F; Mazzarino S; Sangiorgi L; Anello M; Vigneri R
    J Endocrinol Invest; 1998 Dec; 21(11):744-7. PubMed ID: 9972673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glyburide and glipizide in treatment of diabetic patients with secondary failures to tolazamide or chlorpropamide.
    Lev JD; Zeidler A; Kumar D
    Diabetes Care; 1987; 10(6):679-82. PubMed ID: 3123183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experiences in oral antidiabetic therapy with sulphonylureas and biguanides.
    Schöffling K
    Aust N Z J Med; 1971 Aug; 1():Suppl 2:47-56. PubMed ID: 5005131
    [No Abstract]   [Full Text] [Related]  

  • 8. [Sulfonylurea compounds or biguanides in the treatment of type 2 diabetes?].
    Mehnert H
    Dtsch Med Wochenschr; 1989 Jul; 114(27):1086-8. PubMed ID: 2500320
    [No Abstract]   [Full Text] [Related]  

  • 9. Conversion from low-dose insulin therapy to glipizide in patients with non-insulin-dependent diabetes mellitus.
    Rosenstock J; Meisel A; Raskin P
    Am J Med; 1987 Sep; 83(3A):10-5. PubMed ID: 3307402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the therapeutic effects of glibenclamide or the fixed combination of glibenclamide-phenformin with those of gliclazide or chlorpropamide.
    Raptis AE; Tountas N; Yalouris AG; Hadjidakis D; Zaharis A; Miras K; Raptis SA
    Acta Diabetol Lat; 1990; 27(1):11-22. PubMed ID: 2110711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC; Tsang LW; Sorensen JP; Cockram CS
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Behavior of lactate and pyruvate in diabetics during ambulatory treatment with biguanides or with a combination of biguanides and sulfonylureas. II].
    Lunetta M; Presti C; Mughini MT; Mughini L
    Clin Ter; 1980 Jun; 93(6):657-72. PubMed ID: 6775864
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative tolerability profiles of oral antidiabetic agents.
    Krentz AJ; Ferner RE; Bailey CJ
    Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open comparative study of the efficacy and tolerance of a new antidiabetic agent: glipizide.
    De Leeuw I; De Baere H; Decraene P; Lemmens P; Verhaegen H
    Diabetologia; 1973 Sep; ():364-6. PubMed ID: 4204093
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
    DeFronzo RA; Goodman AM
    N Engl J Med; 1995 Aug; 333(9):541-9. PubMed ID: 7623902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.
    Diabetes Care; 1998 Jan; 21(1):87-92. PubMed ID: 9538975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect on metabolic control of second-generation sulfonylurea drugs in patients with NIDDM after secondary failure to first-generation agents.
    Sami T; Kabadi UM; Moshiri S
    J Fam Pract; 1996 Oct; 43(4):370-4. PubMed ID: 8874372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
    Goldstein BJ; Pans M; Rubin CJ
    Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin and sulphonylurea in the therapy of type 2 diabetes.
    Sotaniemi EA; Vierimaa E; Huupponen R; Karvonen I; Vuoti MJ; Rytömaa K
    Diabetes Res Clin Pract; 1990 Mar; 8(3):243-51. PubMed ID: 2111239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.